YAP1 and melanoma: As BRAF mutation is commonly observed in patients with melanoma and its resistance mechanism is associated with YAP activation3,5, vemurafenib-resistant WM3248 melanoma cells, which are cells with acquired resistance6, were utilized to further examine the role of miR-550a-3-5p in BRAF inhibitor resistance.